#United States #New York #Pomerantz LLP #VYKAT XR #Soleno Therapeutics

Pomerantz Law Firm Investigates Soleno Therapeutics

Pomerantz LLP, a renowned law firm specializing in corporate and securities class actions, is currently investigating claims raised on behalf of investors of Soleno Therapeutics, Inc. (NASDAQ: SLNO). This inquiry comes in the wake of serious allegations of securities fraud and other unlawful business practices potentially involving the company’s officers and directors.

Founded by the late Abraham L. Pomerantz, a pioneer in class action litigation, the firm has a rich history of advocating for the rights of investors. The current investigation highlights Pomerantz’s commitment to holding corporations accountable.

Background of the Investigation

The investigation has been initiated as a response to a report released by Scorpion Capital on August 15, 2025. The report criticized Soleno’s primary product, Vykat XR, branding it as overpriced and expressing concerns about its safety for children. In the aftermath of this disturbing revelation, Soleno’s stock experienced a significant decline, plummeting by 7.41%, equating to a loss of $5.73 per share on the same day.

This decline raised alarms among investors who are now seeking to understand the implications of the report and the potential for misconduct at Soleno. The firm is urging those affected to come forward and join the class action to recover possible losses stemming from their investments.

What’s at Stake for Investors?

Investors in Soleno Therapeutics face a precarious situation as the integrity of their investments is called into question. The ongoing investigation by Pomerantz LLP aims to sift through the allegations to determine if the claims of fraud hold merit.

With the pharmaceutical industry being particularly scrutinized for ethical practices and product safety, the stakes are high. Investors have every right to pursue recovery for any losses incurred due to misleading statements or fraudulent activities by the company’s management.

Pomerantz’s Role

Pomerantz LLP prides itself on having pursued justice for investors for more than 85 years, specializing in class-action litigation regarding corporate practices. The firm’s team is equipped to tackle the complexities of securities fraud cases, analyzing the law and available evidence to advocate fiercely for its clients' interests.

Danielle Peyton, a contact at Pomerantz, is encouraging any investors impacted by these developments to reach out. The firm is dedicated to exploring the full scope of the situation concerning Soleno and securing justice for those affected by the company's practices.

What Should Investors Do?

Investors who suspect they may have been misled by Soleno Therapeutics should act quickly to gather their documentation and reach out to the firm for more information. The investigation is in its preliminary stages, and participants in the potential class action may be necessary to secure crucial evidence supporting the claims against the company.

In conclusion, potential stakeholders and investors must remain vigilant. The outcomes of this investigation will likely influence how the market perceives Soleno Therapeutics in the future. Pomerantz LLP's involvement underscores the seriousness of these allegations and the necessity for accountability in corporate governance.

For more information, interested investors are advised to contact Danielle Peyton at Pomerantz LLP via email or phone. Should the investigation yield substantiated claims, affected investors could see significant recourse for their concerns and financial losses, reinforcing the vital role that law firms like Pomerantz play in protecting investor rights.